Tumor-like lesions in a patient diagnosed with multiple sclerosis as non-onset manifestation of the disease
Abstract
Tumefactive multiple sclerosis (MS) is a rare form of the disease and is associated with tumor-like demyelinating lesions larger than 2 cm on MRI-scan. The radiological findings are characterized by the absence of/relatively mild mass effect or perifocal oedema, open-ring pattern contrast enhancement, high ADC(Apparent diffusion coefficient) values. The immunopathogenesis and the prognostic significance of this form of the disease are to be clarified.
We present a clinical case of a 28-year old male, diagnosed with multiple sclerosis in 2013, admitted to the Department of Motor Disorders of MHATNP „St. Naum” on the occasion of acute right-sided hemiparesis, severe for the hand. The control MRI-scan revealed newly appeared ovoid and round lesions in the white brain matter, some of which are tumor-like in size. At the time of hospitalization, the patient was not receiving MS-disease modifying therapy. With this case we illustrate the tumefactive MS as a non-onset manifestation of the disease and an expression of the heterogeneous spectrum of idiopathic demyelinating processes.
References
Milanov, I. Tumoropodobna forma na mnozhestvena skleroza. Mnozhestvena skleroza i avtoimunni demielinizirashti zabolyavaniya na tsentralnata nervna sistema. Meditsina i fizkultura, Sofiya, 2014, 155-156.
Algahtani, H., Shirah, B., Alassiri, A. Tumefactive demyelinating lesions: A comprehensive review. Mult. Scler. Relat. Disord., 2017, 14, 72-79.
Altintas, A., Petek, B., Isik, N., Terzi, M., Bolukbasi, F., Tavsanli, M., Saip, S., Boz, C., Aydin, T., Arici-Duz, O., Ozer, F., Siva, A. Clinical and radiological characteristics of tumefactive demyelinating lesions: Follow-up study. Mult. Scler. J., 2012, 18, 10, 1448-1453.
Barton, J., Hardy, T., Riminton, S., Reddel, S. , Barnett, Y., Coles, A., Barnett, M. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Neurology, 2017, 88, 10, 1004-1006.
Berger, B., Baumgartner, A., Rauer, S., Mader, I., Luetzen, N., Farenkopf, U., Stich, O. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. J. Neuroimmunol., 2015, 282, 118-122.
Brod, S., Lindsey, J., Nelson, F. Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments. Mult. Scler. J. - Exp. Transl. Clin., 2019, 5, 2.
Faissner, S., Hoepner, R., Lukas, C., Chan, A., Gold, R., Ellrichmann, G. Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Ther. Adv. Neurol. Disord., 2015, 8, 5, 233-238.
Fan, X., Mahta, A., De Jager, P., Kesari, S. Rituximab for tumefactive inflammatory demyelination: A case report. Clin. Neurol. Neurosurg., 2012, 114, 10, 1326-1328.
Frederick, M., Cameron, M. Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders. Curr. Neurol. Neurosci. Rep., 2016, 16, 3, 26.
Hardy, T., Chataway, J. Tumefactive demyelination: An approach to diagnosis and management. J. Neurol. Neurosurg. Psychiatry, 2013, 84, 9, 1047-1053.
Lucchinetti, C., Gavrilova, R., Metz, I., Parisi, J., Scheithauer, B., Weigand, S., Thomsen, K., Mandrekar, J., Altintas, A., Erickson, B., König, F., Giannini, C., Lassmann, H., Linbo, L., Pittock, S., Brück, W. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain, 2008, 131, 7, 1759-1775.
Mao-Draayer, Y., Braff, S., Pendlebury, W., Panitch, H. Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology, 2002, 59, 7, 1074-1077.
Masdeu, J., Quinto, C., Olivera, C., Tenner, M., Leslie, D., Visintainer, P. Open-ring imaging sign: Highly specific for atypical brain demyelination. Neurology, 2000, 54, 7, 1427-1433.
Moghadasi, A., Baghbanian, S. Tumefactive demyelinating lesions in a patient with multiple sclerosis receiving natalizumab. Acta Neurol. Belg., 2019, 119, 1, 137-139.
Pilz, G., Harrer, A., Wipfler, P., Oppermann, K., Sellner, J., Fazekas, F., Trinka, E., Kraus, J. Tumefactive MS lesions under fingolimod: A case report and literature review. Neurology, 2013, 81, 19, 1654-1658.
Poser, S., Lüer, W., Bruhn, H., Frahm, J., Brück, Y., Felgenhauer, K. Acute demyelinating disease. Classification and non‐invasive diagnosis. Acta Neurol. Scand., 1992, 86, 6, 579-585.
Sánchez, P., Meca-Lallana, V., Barbosa, A., Manzanares, R., Palmí, I., Vivancos, J. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature. J. Neurol. Sci., 2017, 381, 32-38.
Sempere, A., Feliu-Rey, E., Sanchez-Perez, R., Nieto-Navarro, J. Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange. J. Neurol. Neurosurg. Psychiatry, 2013, 84, 12, 1338-1339.
Siffrin, V., Müller-Forell, W., Von Pein, H., Zipp, F. How to treat tumefactive demyelinating disease? Mult. Scler. J., 2014, 20, 5, 631-633.
Suh, C., Kim, H., Jung, S., Choi, C., Kim, S. MRI findings in tumefactive demyelinating lesions: A systematic review and meta-analysis. Am. J. Neuroradiol., 2018, 39, 9, 1643-1649.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Elena Zlatareva, I. Milanov, S. Ivanova, D. Georgiev
This work is licensed under a Creative Commons Attribution 4.0 International License.
